

1 N Gene Target Failure (NGTF) for detection of Omicron: a 2 way out for the 'stealth' too?

3 Authors:

4 *Shivangi Harankhedkar^{1,2}, Gaurav Chatterjee^{1,2}, Sweta Rajpal^{1,2}, Afreen Khan^{1,2}, Tuhina*
5 *Srivastava¹, Sumeet Mirgh^{2,3}, Anant Gokarn^{2,3}, Sachin Punatar^{2,3}, Nitin Shetty^{2,4}, Amit Joshi^{2,3},*
6 *Sudhir Nair^{2,5}, Vedang Murthy^{2,6}, Prashant Tembhare^{1,2}, Ashwini More⁷, Sujeet Kamtalwar⁷,*
7 *Preeti Chavan⁹, Vivek Bhat^{2,9}, Amar Patil⁷, Sachin Dhuma⁶, Prashant Bhat⁷, Papagudi*
8 *Subramanian^{1,2}, Rachana Tripathi¹⁰, Shesheer Munipally¹⁰, Sumeet Gujral^{1,2}, Navin Khattry^{2,3},*
9 *Sudeep Gupta^{2,3}, Nikhil Patkar^{1,2*}*

10
11 *Corresponding author
12

13 Affiliations:

14 ¹Haematopathology Laboratory, ACTREC, Tata Memorial Centre, Navi Mumbai, India
15 ²Homi Bhabha National Institute (HBNI), Mumbai, India
16 ³Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
17 ⁴Department of Radiodiagnosis, Tata Memorial Centre, Mumbai, India
18 ⁵Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India
19 ⁶Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India
20 ⁷Department of General Medicine, ACTREC, Tata Memorial Centre, Navi Mumbai, India
21 ⁸Department of Laboratory Medicine, ACTREC, Tata Memorial Centre, Navi Mumbai, India
22 ⁹Department of Microbiology, ACTREC, Tata Memorial Centre, Navi Mumbai, India
23 ¹⁰Huwel Lifesciences Pvt Ltd
24
25

26 **Keywords:** SARS-CoV-2 genome sequencing, Omicron, stealth Omicron, N gene target failure, SGTF,
27 RT-PCR screening for Omicron
28

29 **Running Title:** N Gene Target Failure (NGTF) for Omicron Diagnosis
30
31

32 Corresponding author:

33 Dr Nikhil Patkar MD, DNB
34 Clinician Scientist & Professor
35 Haematopathology Laboratory,
36 ACTREC, Tata Memorial Centre, Kharghar, Maharashtra, India, Pin: 410210
37 Email: nvpatkar@gmail.com, npatkar@actrec.gov.in
38 Phone: +91-22-27405000, Ext: 5789
39

40
41 Word count (abstract): 149

42 Word count (manuscript): 1383

43

44 **Abstract**

45

46 S-gene target failure (SGTF) is neither specific nor accurate for identification of Omicron

47 lineage of SARS-CoV-2. We observed N-gene target failure (NGTF) in 402 out of 412 SARS-

48 CoV2 positive cases from December to mid-January 2022 using a commercially available

49 assay. This phenomenon was not observed with more than 15,000 cases tested previously. We

50 sequenced the genome of five samples with NGTF and compared these results with six cases

51 where NGTF was not seen. We confirm that cases with NGTF were the Omicron lineage while

52 cases with preserved N-gene amplification belonged to Delta lineage. We discovered that the

53 ERS31-33 deletion (nucleotide 28362-28370del) overlaps with N gene probe used, explaining

54 NGTF. As the 'stealth' Omicron variant also harbors ERS31-33 deletion, this approach will work

55 for the detection of 'stealth' Omicron variant as well. We suggest that NGTF can be used as a

56 low cost, rapid screening strategy for detection of Omicron.

57

58 **1. Introduction**

59 The ongoing COVID19 pandemic has witnessed the emergence of novel strains due to the
60 accumulation of mutations in the SARS-CoV-2 genome [1]. Since December 2020, variants of
61 concern (VOC) have been discovered, namely, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1),
62 Delta (B.1.617.2). A variant first reported from South Africa was notified to the WHO late in
63 November 2021. Based on genome sequencing this strain was designated with PANGOLIN
64 lineage B.1.1.529 and called the “Omicron” variant (Nextclade strain 21K) [2] [3]. As compared
65 to the original Wuhan strain of SARS-CoV-2, the Omicron variant distinctively harbors a higher
66 number of mutations and is highly transmissible resulting in a higher infectivity rate [4] [5]. This
67 has resulted in a sharp spike in the number of cases all over the globe. This Omicron variant is
68 characterized by more than thirty mutations (including single nucleotide variants as well as
69 insertions and deletions) in the spike protein-coding regions which has raised concerns
70 regarding higher transmissibility and efficacy of vaccines. Furthermore, recent evidence has
71 also emerged that therapeutic monoclonal antibodies have a minimal response against the
72 Omicron variant, presumably due to mutations in the spike protein-encoding regions [5]. This
73 creates the possibility of a clinical need for diagnosis of Omicron variant and distinguishing this
74 from other SARS-CoV-2 variants.

75 Although the definitive evidence of strain evolution can be obtained by genome sequencing this
76 technique is time-consuming and is available to only a fraction of the laboratories due to the
77 high expertise required to perform this assay. Real-time polymerase chain reaction (RT-PCR)
78 based testing remains the mainstay for relatively rapid testing and community diagnosis.

79 In India (and presumably all over the world), there is a paucity of commercially available kits that
80 can specifically detect the Omicron variant. It has been suggested that S-gene amplification
81 failure on RT-PCR is a surrogate method to suspect Omicron. However, S-gene amplification
82 failure has also been observed (when using the TaqPath COVID-19 Combo Kit, Thermo Fisher)

83 with the alpha variant of SARS-CoV-2 [6]. In this manuscript, we describe a commercially
84 available RT-PCR assay that can be used as a rapid screening tool to detect the Omicron
85 variant as a result of N-gene amplification failure. We demonstrate sequence level evidence that
86 this approach detects the Omicron variant and reliably distinguishes it from the Delta variant of
87 SARS-CoV-2.

88

89 **2. Methods:**

90 Nasopharyngeal and oropharyngeal swabs were received in either viral transport media (VTM)
91 or molecular transport media (MTM) from the fever clinic at the discretion of the treating
92 physician. The testing cohort included hospital staff as well as cancer patients. Real-time
93 polymerase chain reaction (RT-PCR) was performed using a commercially available SARS-
94 CoV-2 assay (Huwel Life Sciences). A total of 15144 tests were carried out over a period of
95 around 23 months (March 2020- mid Jan 2022). Coinciding with the third wave of the pandemic
96 in India, a rise in positivity rate was observed (412 positives out of 1484 samples tested
97 between December 01st 2021 and January 16th, 2022, positivity rate of 27.76%) (Figure 1).
98 Eleven cases diagnosed as positive for SARS-CoV-2 by RT-PCR in December 2021 were
99 selectively chosen for viral genome sequencing (five with N-gene amplification failure and six
100 cases without N-gene amplification failure). Amplicon based viral whole-genome sequencing
101 was carried out as per protocols provided by the ARTIC network initiative [7]. Library
102 preparation was performed using the QIAseq FX library kit (Qiagen, Germany) followed by
103 paired-end sequencing on an Illumina MiSeq platform at a targeted depth of 0.3 million reads
104 per sample. For analysis of genomic data, the raw fastq reads were processed for quality
105 checks and parsed through the bioinformatics pipeline for the generation of consensus fasta
106 sequences. Alignment to the reference genome sequence (GenBank: MN908947.3, RefSeq:
107 NC_045512.2; Wuhan-Hu-1 genome) was done using using BWA-MEM algorithm (v.0.7.17).
108 SAM files were processed further using Samtools (v.1.9) and variants were called using iVar
109 (v.1.2) at a minimum alternative frequency of 0.01.

110 Lastly, Nextclade web application was used to process the fasta sequences for identification of
111 clade and mutation calling. The Phylogenetic Assignment of the named Global Outbreak
112 LINEages (PANGOLIN) method of lineage classification was followed [8]. Due approval by
113 Institutional Ethics Committee of Tata Memorial Centre was obtained for this study.

114

115 **3. Results:**

116 We have performed over 15000 tests for detection of SARS-CoV-2 RNA, using a commercially
117 available RT-PCR kit (Huwel Life Sciences, Hyderabad, India), which involves the detection of E
118 (Envelope) and N (Nucleocapsid) genes of the virus (Figure 2). A positive result has
119 conventionally required amplification in the E and N gene both. Overall positivity rate of 16.2%
120 was observed during last two years. Towards end of December 2021, as Omicron variant began
121 rising worldwide, we also noticed a sharp rise in the number of positive cases. Positivity rate in
122 January 2022 (1st to 16th January 2022) escalated to 47.24% (386 out of the total 817 samples)
123 from the previous 3.89% in December 2021 (26 positives out of 667 samples, Figure 1). We
124 observed that cases diagnosed from December onwards, showed amplification of E gene alone
125 (N gene target failure, NGTF), a clear divergence from our trend of the past two years (Figure
126 2). NGTF was observed in 402 out of the 412 positive cases (between 1st of December 2021 to
127 16th of January 2022), while the remaining ten showed amplification in both E and N genes
128 (Figure 3). On examination of N-gene primer and probe sequences we confirmed that the
129 ERS31-33 deletion (nucleotide 28362-28370del), characteristic of Omicron variant, overlapped
130 with the N gene probe used, resulting in NTGF. We further selected five cases with NTGF, and
131 six cases showing amplification in both E and N genes for genome sequencing. All five cases
132 with NTGF were confirmed on genome sequencing as consistent with Omicron variant (BA.1
133 lineage), whereas all six cases with both N and E gene amplification belonged to Delta.

134

135

136 **4. Discussion**

137 The S gene target failure (SGTF) resulting from the HV69-70del is predominantly considered for
138 identifying Omicron variant by most commercial kits [9]. However, mutations also affect other
139 genes including ORF1ab, E and N in the Omicron variant [3]. Our findings confirm that the
140 cases showing N gene dropout on RT-PCR (Huwel Life Sciences) are consistent with the
141 Omicron variant, BA.1 lineage. The N gene probe overlaps with the ERS31-33del observed in
142 Omicron, thus explaining the N gene target failure phenomenon (Figure 4). An important point
143 here is that the S gene HV69-70del, responsible for SGTF, is not specific for the Omicron
144 variant and is also observed in the Alpha (B.1.1.7) and Eta (B.1.525) variants, whereas the N
145 gene ERS31-33del resulting in NTGF described here is not seen in any other SARS-CoV-2
146 variants of concern or interest. These findings reflect that Omicron variant can be reliably
147 reported in cases showing NGTF by the current kit (Huwel Life Sciences), while dual
148 amplification in E gene and N gene (or rarely N gene alone) is likely to represent the presence
149 of delta/ non-Omicron variant. This separation does hold a clinical value in view of the reported
150 differences in clinical severity and communicability between the two variants [10].

151 The second Omicron variant of the BA.2 lineage, termed 'stealth' Omicron, is genetically distinct
152 from the BA.1 lineage and reported to escape detection on routinely used PCR kits as it does
153 not harbour HV69-70del, therefore not resulting in S gene dropout [6] [11]. We did not encounter
154 Omicron BA.2 lineage in our sequenced cases, however, we are confident that the NTGF by our
155 RT-PCR method can be utilized to detect the BA.2 lineage as well, as the ERS31-33del in N
156 gene is observed in both BA.1 and BA.2 lineages of Omicron variant [3]. We also emphasize
157 that preservation of N gene or its dropout would depend on further viral genetic mutations and
158 the probe design used for the gene in individual kits and that these findings concern the NTGF
159 in the present kit used in the current clinical scenario only.

160

161 Our findings strongly highlight the possible fluctuations in the interpretation of RT-PCR results
162 which can be encountered by laboratories involved in SARS-CoV-2 detection worldwide,
163 especially as new SARS-CoV-2 variants with higher mutation load emerge in future. Following
164 proper validation, the channelization of available commercial RT-PCR kits can be used as
165 surrogates for detection of Omicron variant or any future variant at community-scale, thus
166 reducing the burden on sequencing laboratories.

167 **5. Conclusion**

168 We describe a readily available RT-PCR strategy for rapid diagnosis of Omicron variant based
169 on N-gene amplification failure.

170

171 The authors declare that they have no competing financial and non-financial interests.

172 **References**

- 173 [1] Cascella M, Rajnik M, Aleem A, Dulebohn S, Di Napoli R. Features, evaluation, and
174 treatment of coronavirus (COVID-19). StatPearls. 2022 Jan 5.
- 175 [2] [https://www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern)
176 cov-2-variant-of-concern
- 177 [3] CoVariants (c) 2020-2022 website for SARS-CoV-2 variants by Emma Hodcroft
178 <https://covariants.org/> (last accessed on Jan 30th 2022)
- 179 [4] Ciling A, Khalid MM, Sreekumar B, Kumar GR, Silva I, Milbes B, Kojima N, Hess V,
180 Shacreaw M, Lopez L. Omicron mutations enhance infectivity and reduce antibody
181 neutralization of SARS-CoV-2 virus-like particles. medRxiv. 2021 Jan 1.
- 182 [5] Syed AM, Ciling A, Khalid MM, Sreekumar B, Kumar GR, Silva I, Milbes B, Kojima N,
183 Hess V, Shacreaw M, Lopez L. Omicron mutations enhance infectivity and reduce
184 antibody neutralization of SARS-CoV-2 virus-like particles. medRxiv. 2021 Jan 1.
- 185 [6] Thomas E, Delabat S, Carattini YL, Andrews DM. SARS-CoV-2 and variant
186 diagnostic testing approaches in the United States. Viruses. 2021 Dec;13(12):2492.
- 187 [7] Itokawa K, Sekizuka T, Hashino M, Tanaka R, Kuroda M. Disentangling primer
188 interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR.
189 PloS one. 2020 Sep 18;15(9):e0239403.
- 190 [8] Shetty A, SARS-CoV2 infection in Mumbai. Correlation of Viral Genomic Sequencing
191 Data and Clinical Outcomes, *International Journal of Clinical Practice* (article in
192 press)
- 193 [9] Petrillo, Mauro, Querci, Maddalena, Corbisier, Philippe, Marchini, Antonio, Buttinger ,
194 Gerhard, & Van den Eede, Guy. (2021). In Silico Design of Specific Primer Sets for
195 the Detection of B.1.1.529 SARS-CoV-2 Variant of Concern (Omicron) (Version 01).
196 Zenodo.

197 [10] Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, Amoako DG, Everatt J,
198 Bhiman JN, Scheepers C, Tebeila N. Early assessment of the clinical severity of the SARS-
199 CoV-2 Omicron variant in South Africa. medRxiv. 2021 Jan 1.

200 [11] <https://github.com/cov-lineages/pango-designation/issues/361>

201 All authors have equally contributed to this work.

202
203
204

205 **Figure legends**

206 Figure 1: Week wise SARS-CoV-2 positivity rate showing sharp rise in cases towards late
207 December 2021.

208

209 Figure 2: a: Case showing amplification in both E and N genes along with the internal control
210 (RNAse P) amplification by RT-PCR. b: A case displaying N gene target failure (NGTF), with
211 isolated amplification of E gene (analyzed on Light Cycler®96 Version 1.1.0.1320, Roche
212 Diagnostics).

213

214 Figure 3: Comparative bar graph showing sharp rise in number of cases showing N gene drop
215 out or N gene target failure (NGTF) compared to those without NGTF.

216

217 Figure 4: Aligned sequence reads in a case showing N gene drop out, depicting the presence of
218 9 nucleotide deletion (NC_045512.2:28,362-28,370) as seen in Integrated Genome Viewer
219 (IGV) tool for visualization of indexed BAM files. Alignment was done against alignment with
220 SARS-CoV2 reference genome (NC_045512.2). The top panel shows the N gene primer and

221 probe sequences used in the commercial RT-PCR kit (Huwel Life Sciences). The presence of
222 this deletion overlaps with the highlighted sequence N gene probe.

223

224


225



Percentage of positive cases


60.00
50.00
40.00
30.00
20.00
10.00
0.00

1 - 7 Dec 2021
8 - 14 Dec 2021
15 - 21 Dec 2021
21 - 28 Dec 2021
29 - 31 Dec 2021
1 - 7 Jan 2022
8 - 14 Jan 2022
15 - 16 Jan 2022

Preprint doi: <https://doi.org/10.1101/2022.01.08.22298961>; this version posted February 1, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).







medRxiv preprint doi: <https://doi.org/10.1101/2022.01.12.22010001>; this version posted February 1, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Forward primer
GTTTGGTGGACCOCTCAGATT

N gene Probe
TAACCAGAATGGAGAACGCAGTGGG

Reverse Primer
ATACTGCGTCTTGGTTCACC

